Dynavax Technolo Stock Price, News & Analysis

Dynavax (NASDAQ: DVAX) reported Q3 2025 results and announced a new $100 million share repurchase program on Nov 5, 2025. HEPLISAV-B quarterly net product revenue was $90.0M, up 13% YoY, with U.S. total market share ~46% and retail share ~63%. Full-year HEPLISAV-B guidance remains $315–$325M. GAAP net income was $26.9M and adjusted EBITDA was $35.5M for Q3. Cash, cash equivalents and marketable securities totaled $647.8M at Sept 30, 2025. Dynavax entered an exclusive license with Vaxart for an oral COVID-19 vaccine (upfront $25M + $5M equity; $50M contingent payment after Phase 2b), and presented positive topline Phase 1/2 shingles data for Z-1018 at IDWeek.

Dynavax (Nasdaq: DVAX) entered an exclusive worldwide license for Vaxart's oral COVID-19 vaccine program on Nov 5, 2025, paying a $25M upfront license fee plus a $5M equity investment. Vaxart will fund and run the ongoing Phase 2b trial (≈5,400 participants) through an EOP2 meeting with FDA; topline data are expected in late 2026. After the Phase 2b readout Dynavax may elect to assume development, paying an additional $50M and potential milestones up to $195M (regulatory) and $425M (sales) plus low‑to‑mid‑teens royalties.

Dynavax (Nasdaq: DVAX) will report third quarter 2025 financial results on Wednesday, November 5, 2025 after U.S. market close. The company will host a conference call and live audio webcast the same day at 4:30 p.m. ET / 1:30 p.m. PT. Investors can access the live webcast via the Investors > Events & Presentations page at https://investors.dynavax.com/events-presentations. A replay will be available for 30 days after the event. Participants must register to dial into the call and are advised to join about 10 minutes early. Contact information for investor/media inquiries is provided.

Business summary: Dynavax is a commercial-stage biopharmaceutical company with two commercial products: HEPLISAV-B vaccine and CpG 1018 adjuvant.

Dynavax (Nasdaq: DVAX) presented positive topline Part 1 data from its Phase 1/2 trial of shingles vaccine candidate Z-1018 at IDWeek 2025 and has initiated Part 2.

Key points: Z-1018 (multiple gE doses with CpG 1018 ± alum) showed anti-gE IgG and gE-specific CD4+ T-cell vaccine response rates comparable to Shingrix at four weeks after dose 2, plus robust polyfunctional CD4+ responses and a favorable tolerability profile. Dynavax advanced a 100 mcg gE + CpG 1018 + alum, 0/8-week regimen into Part 2, which has dosed first participants and plans ~324 adults aged 70+ with topline data expected in H2 2026.

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3rd at 4:30 p.m. ET.

The company currently markets two key products: HEPLISAV-B, an approved hepatitis B vaccine for adults in the US, EU, and UK, and CpG 1018 adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.

Dynavax Technologies (Nasdaq: DVAX) announced positive topline results from Part 1 of its Phase 1/2 clinical trial for Z-1018, its novel shingles vaccine candidate, demonstrating comparable efficacy to Shingrix with better tolerability. The trial's selected dose achieved a 100% humoral vaccine response rate and 89.7% cellular immune response rate.

Z-1018 showed significantly lower adverse reactions compared to Shingrix, with only 12.5% reporting grade 2-3 local reactions versus 52.6% for Shingrix, and 27.5% reporting grade 2-3 systemic reactions versus 63.2% for Shingrix. The company will advance the 100 mcg dose with CpG 1018 and alum adjuvant using an 8-week dosing interval to Part 2 of the trial in adults 70+ years, scheduled for 2H 2025.

Dynavax (NASDAQ:DVAX) reported strong Q2 2025 financial results, highlighted by record HEPLISAV-B quarterly net product revenue of $92 million, representing 31% year-over-year growth. The company refined its full-year 2025 HEPLISAV-B revenue guidance to $315-325 million.

Total Q2 revenues reached $95.4 million, with GAAP net income of $18.7 million ($0.16 per share). HEPLISAV-B's U.S. market share increased to 45%, up from 42% in Q2 2024. The company expects the U.S. hepatitis B vaccine market to expand to over $900 million in annual sales by 2030.

Key pipeline updates include anticipated top-line results from Phase 1/2 shingles vaccine trial in August 2025 and completed dosing in Part 1 of the pandemic influenza adjuvant program trial.

Dynavax Technologies (NASDAQ:DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Participants are advised to join approximately 10 minutes before the call starts. The webcast will be accessible through the company's investor relations website, with a replay available for 30 days.

Dynavax currently markets two commercial products: HEPLISAV-B vaccine for hepatitis B prevention and CpG 1018 adjuvant, which is used in multiple COVID-19 vaccines.

Dynavax Technologies Corporation (DVAX) announced that stockholders have elected all four director nominees - Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun - to the Company's Board of Directors at their 2025 Annual Meeting. The preliminary voting results also indicate stockholder approval for all other Board-recommended proposals, including the phased declassification of the Board. The company views this outcome as validation of their strategic plan. The results remain preliminary until final tabulation and certification by the independent Inspector of Elections, with final results to be filed on Form 8-K with the SEC. Goldman Sachs & Co. LLC and Cooley LLP are serving as financial advisor and legal counsel, respectively.